Future Directions for Serotonin and Antidepressants

被引：46

作者：

Artigas, Francesc ^{[1
]}

机构：

[1] CSIC, Ctr Invest Biomed Red Salud Mental CIBERSAM, Dept Neurochem & Neuropharmacol, IIBB,IDIBAPS, Rossello 161,6th Floor, Barcelona 08036, Spain

来源：

ACS CHEMICAL NEUROSCIENCE | 2013年 / 4卷 / 01期

关键词：

RECEPTORS; REUPTAKE; ANTAGONIST; ACTIVATION; INHIBITOR; ONSET; LONG;

D O I：

10.1021/cn3001125

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Despite the widespread use of antidepressant medications that block serotonin (5-hydroxytryptamine; 5-HT) and/or norepinephrine (NE) transporters, such as SSRIs (selective serotonin reuptake inhibitors) or SNRIs (serotonin and norepinephrine reuptake inhibitors), the underlying neurobiological basis of action of these agents is poorly understood. Increases in serotonergic function are hypothesized to have beneficial effects on depressive symptoms. However, which of the 14 different neuronal receptors sensitive to 5-HT accounts for the therapeutic effects of SSRIs and SNRIs remains undetermined. The development of drugs that activate or block specific 5-HT receptors may help to circumvent the two main limitations of current antidepressants: low efficacy and delayed onset of therapeutic action. What follows is a short summary of the author's views on this matter.

引用

页码：5 / 8

页数：4

共 21 条

[1]

Andersen B, 1990, J AFFECT DISORDERS, V18, P289

[2] Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists [J].

Artigas, F ;

Romero, L ;

deMontigny, C ;

Blier, P .

TRENDS IN NEUROSCIENCES, 1996, 19 (09) :378-383

[3] How does pindolol improve antidepressant action? [J].

Artigas, F ;

Celada, P ;

Laruelle, M ;

Adell, A .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (05) :224-228

[4] Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents [J].

Bonaventure, Pascal ;

Kelly, Lisa ;

Aluisio, Leah ;

Shelton, Jonathan ;

Lord, Brian ;

Galici, Ruggero ;

Miller, Kirsten ;

Atack, John ;

Lovenberg, Timothy W. ;

Dugovic, Christine .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 321 (02) :690-698

[5] Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects [J].

Bortolozzi, A. ;

Castane, A. ;

Semakova, J. ;

Santana, N. ;

Alvarado, G. ;

Cortes, R. ;

Ferres-Coy, A. ;

Fernandez, G. ;

Carmona, M. C. ;

Toth, M. ;

Perales, J. C. ;

Montefeltro, A. ;

Artigas, F. .

MOLECULAR PSYCHIATRY, 2012, 17 (06) :612-623

[6] F15599, a preferential post-synaptic 5-HT1A receptor agonist: Activity in models of cognition in comparison with reference 5-HT1A receptor agonists [J].

Depoortere, Ronan ;

Auclair, Agnes L. ;

Bardin, Laurent ;

Colpaert, Francis C. ;

Vacher, Bernard ;

Newman-Tancredi, Adrian .

EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 (09) :641-654

[7] 5-HT2B receptors are required for serotonin-selective antidepressant actions [J].

Diaz, S. L. ;

Doly, S. ;

Narboux-Neme, N. ;

Fernandez, S. ;

Mazot, P. ;

Banas, S. M. ;

Boutourlinsky, K. ;

Moutkine, I. ;

Belmer, A. ;

Roumier, A. ;

Maroteaux, L. .

MOLECULAR PSYCHIATRY, 2012, 17 (02) :154-163

[8]

GRAM LF, 1986, PSYCHOPHARMACOLOGY, V90, P131

[9]

Haddjeri N, 1998, J NEUROSCI, V18, P10150

[10] Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors [J].

Llado-Pelfort, L. ;

Assie, M-B ;

Newman-Tancredi, A. ;

Artigas, F. ;

Celada, P. .

BRITISH JOURNAL OF PHARMACOLOGY, 2010, 160 (08) :1929-1940

← 1 2 3 →